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Background. Neuropsychiatric symptoms are common in people with dementia, and pain is thought to be an important underlying
factor. Pain has previously been associated with agitation, and pain treatment has been shown to ameliorate agitated behaviour. So
far, the association between pain and psychosis and the effect of pain treatment on psychotic symptoms is unclear. Furthermore,
the impact of opioid treatment on psychosis is not established. Aim. To investigate the efficacy of a stepwise protocol for treating
pain (SPTP) on psychosis and agitation measured with the Neuropsychiatric Inventory, Nursing Home version, and to explore the
impact of opioid analgesics on psychosis.Method. Secondary analyses are from a cluster-randomised controlled trial including 352
patients with advanced dementia and agitation from 18 nursing homes in Western Norway. The intervention group received pain
treatment according to SPTP. Results. Pain was associated with disinhibition (adjusted OR: 1.21, 95% CI: 1.10–1.34) and irritability
(adjusted OR: 1.10, 95% CI: 1.01–1.21) at baseline. Pain treatment reduced agitation (p < 0.001, df = 1; 300) and aberrant motor
behaviour (p = 0.017, df = 1; 300). Psychosis was reduced in people with at least one symptom at baseline (p = 0.034, df = 1; 135).
The use of opioid analgesics did not increase psychotic symptoms. Study Registration. This trial is registered with ClinicalTrials.gov
(NCT01021696), Norwegian Medicines Agency, EudraCT (EudraCTnr: 2008-007490-20).
1. Introduction
Neuropsychiatric symptoms (NPS) are a feature in many
neurodegenerative diseases, among other dementia, where
over 90% of patients suffer from at least one NPS during the
course of their disease [1]. NPS can be distressing for both
patients and family alike and is often the main reason for
admission to a nursing home (NH) [2]. NPS can be clustered
in different ways. These clusters are most commonly defined
by symptoms that present concurrently, like mood symptoms
such as depression and anxiety, agitation symptoms such as
aggression and irritability, and psychosis symptoms such as
delusion and hallucination [3–6].
The aetiology of NPS is largely unknown, but factors like
neuropathological changes in the brain, unmet psychosocial
needs, and pain are thought to play a role [7]. Despite
the multiple potential underlying factors, NPS are often
treated with antipsychotic drugs with potential harmful side
effects [8].This highlights the importance of investigating the
relationship between NPS and possible underlying treatable
causes, such as pain, to avoid unnecessary antipsychotic drug
use [9–11].
People in the later stages of dementia often reside in NHs
and frequently experience pain, with 30–60% suffering daily
from pain [12–14]. The cognitive decline with a subsequent
loss of communicative abilities puts people with dementia at
an increased risk of suffering from untreated pain [15, 16].
Research demonstrates that pain in people with dementia
can act as a trigger for NPS such as agitation and mood
symptoms [17, 18]. However, the relationship between pain
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and psychosis symptoms is less well studied, and only an
association between pain and delusion has previously been
described. Tosato et al. investigated the association between
pain and NPS in NH patients with cognitive impairment and
found pain to be associated with delusion [19]. In contrast,
Cohen-Mansfield et al. found no association between pain
and psychosis symptoms in an adult day care population (≥60
years old) residing in the community [20].
Our own research demonstrated the efficacy of individual
pain treatment on behavioural disturbances in NH patients
with advanced dementia and found that pain treatment
ameliorated agitation as assessed by the Cohen-Mansfield
Agitation Inventory (CMAI) [9]. Secondary analyses showed
that pain treatment also reduced verbal aggression and rest-
lessness [10]. Mood symptoms such as depression, sleep and
appetite disturbances, measured with the Neuropsychiatric
Inventory, Nursing Home version (NPI-NH) [11], and pain
intensity assessed by theMobilisationObservation Behaviour
Intensity Dementia-2 (MOBID-2) Pain Scale [13] were also
found to be reduced.The effect of pain treatment on psychosis
and agitation symptoms measured by NPI-NH has, however,
not yet been investigated.
Although there are no official guidelines for pain treat-
ment in people with dementia, the use of opioid analgesics
in pain treatment is recommended in guidelines for older
people [21–23]. However, some physicians can be reluctant
to prescribe these drugs, often due to the fear of possible
side effects such as delirium, which also includes psychotic
symptoms such as hallucination and delusion [24, 25]. The
association between opioid analgesics and psychosis can
therefore give relevant information regarding delirium as a
potential side effect of opioid drug use.
The primary aim of this study was to investigate the
efficacy of pain treatment on psychosis and agitation and
the association between pain, psychosis, and agitation in
people with advanced dementia. In addition, we investigated
whether the use of opioid analgesics increased the prevalence
of delusion and hallucination in people with dementia. We
hypothesized an association between pain and agitation at
baseline, but not between pain and psychosis, and suggested
that pain treatment will reduce symptoms of agitation, but
not symptoms of psychosis. We also hypothesized that the
use of opioid analgesics does not increase the prevalence of
hallucination and delusion.
2. Method
We conducted secondary analyses from a cluster-randomised
controlled trial (RCT), investigating the efficacy of treat-
ing pain on behavioural disturbances in NH patients with
advanced dementia from 18 NHs in Western Norway. For a
more detailed description of the study procedure, we refer to
previous publications [9, 11, 13]. In brief, patients included
in this study had moderate to severe dementia as defined
by the Diagnostic and Statistical Manual of mental disor-
ders, 4th edition (DSM-IV); Functional Assessment Staging
Test (FAST) score ≥ 4 [26]; Minimental State Examination
(MMSE) score ≤ 20 [27], and clinically relevant behavioural
disturbances as defined by a score ≥ 39 on CMAI [28].
Patients were excluded if they had an advanced medical dis-
order with expected survival ≤ 6 months, severe psychiatric
or neurological disorder, hepatic or renal failure, a score ≥
8 on the aggression item of the NPI-NH, with aggression as
the predominant symptom [29], or allergy to paracetamol,
morphine, buprenorphine, or pregabalin.
2.1. Study Design. Each NH unit was defined as a single
cluster and was randomised to either intervention or control.
Randomisation was performed by a statistician using Stata
version 8, by generating a list of random numbers used
for allocating each cluster to either intervention or control.
The intervention group received individual pain treatment
according to a stepwise protocol for treating pain (SPTP)
for 8 weeks, followed by a 4-week washout period where
analgesics were reverted back to preintervention treatment.
The control group received treatment as usual.The SPTP was
based on recommendationsmade by theAmericanGeriatrics
Society [22]. According to assessment of current medication
and degree of pain, the patient was allocated to one of four
steps, receiving either paracetamol (Paracetamol), extended
release morphine (Dolcontin), buprenorphine transdermal
patch (Norspan) for patients with swallowing difficulties, or
pregabalin (Lyrica) for patients with suggested neuropathic
pain. Physicians were instructed to keep the prescription
unchanged if possible. Use of as-needed analgesics was not
prohibited and was monitored during the study.
2.2. Outcome Measures. The primary outcome measure was
NPS as measured by the NPI-NH [29]. The NPI-NH rates
the frequency (𝐹) and severity (𝑆) of twelve different NPS.
Frequency is rated on a scale from 1 to 4, where 1 represents
occasionally (less than once a week) and 4 represents very
frequent (daily ormore often). Severity ismeasured on a scale
from 1 to 3, where 1 represents mild (causes little stress for
the patient) and 3 represents severe (puts very much stress on
the patient and cannot easily be diverted by caregivers). The
frequency and severity scores are multiplied (𝐹×𝑆) to give an
item score for each NPS, where a score ≥ 4 was viewed as a
clinically significant symptom [30].
The NPS measured by NPI-NH were clustered in three
groups: agitation (aggression, disinhibition, irritability, and
aberrant motor behaviour), psychosis (delusion, hallucina-
tion, and euphoria), and mood (depression, anxiety, apathy,
and sleep and appetite disturbances), according to factor
analyses by Cheng et al. [6].
Pain intensity was assessed by the MOBID-2 Pain Scale
[31–33]. This is a nursing staff-administered pain tool, con-
sisting of two parts. The first part assesses pain originating
from the musculoskeletal system during five active guided
movements. The second part assesses pain that might be
related to internal organs, head, and skin based on the care-
givers’ observation during the last week. Taking all items into
account, the caregiver rated the patients’ pain on a Numerical
Rating Scale (NRS) ranging from 0 to 10, where 0 represented
no pain and 10 the worst pain imaginable. This tool has been
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thoroughly tested for its psychometric properties and showed
good validity, reliability, and responsiveness [32, 33].
All assessments were conducted at baseline and Weeks 2,
4, 8, and 12 by the primary caregivers who knew the patient
best in collaboration with a specialised study nurse.
2.3. Statistics. Differences in baseline characteristics were
explored using an independent sample t-test for normally dis-
tributed variables; a Chi-squared test was used for categorical
variables, and a Mann-WhitneyU test was used for nonpara-
metric variables. Associations between pain, psychosis, and
agitation at baseline were investigated by using crude and
adjusted logistic regression. Each symptom of psychosis and
agitation represented the dependent variable, while total pain
intensity, assessed by MOBID-2, represented the explanatory
variable. Associationswere adjusted for age, gender, dementia
severity (assessed byMMSE and FAST), and activities of daily
living (ADL) function assessed by Barthels ADL index [34].
The changes in 𝐹 × 𝑆 score between the intervention and
control groups from baseline toWeek 8 were compared using
the Mann-Whitney U test. The association between opioid
analgesics and delusion and hallucination was evaluated at
baseline and Week 8 using logistic regression. Associations
were adjusted for age, gender, dementia severity (MMSE and
FAST), ADL function (Barthels ADL index), and pain inten-
sity (MOBID-2). Statistic calculations were performed using
the Statistical Package for Social Sciences (SPSS) version 22.
3. Ethics
Informed consent was obtained from patients who were
cognitively able to understand the possible risks and benefits
of the study. Consent was, if possible, obtained in a meeting
where next of kin was present as well. A presumed consent
was obtained from next of kin, or a legal guardian, if the
patient was not able to give an informed consent. All consents
were obtained in accordance with local law, approved by the
Regional Ethical Committee for Medical Ethics in Western
Norway (REK-Vest 248.08), and authorised by the participat-
ing institutions’ review board.
4. Results
Three hundred and fifty-two patients from 60 NH units were
included. Units were randomised to either intervention or
control, generating 177 patients in the control group and 175
patients in the intervention group. With the exception of age
(p = 0.022), we found no differences between the two groups.
Baseline characteristics are described in Table 1. During the
intervention period, 13 patients in the control and 25 in
the intervention group were excluded, with no significant
differences between the two groups [9]. At baseline, 71 people
in the control group (40%) and 83 people in the intervention
group (47%) had one or more symptoms of psychosis, while
128 people in the control group (72%) and 137 people in
the intervention group (78%) had one or more symptoms of
agitation.Themost prevalent symptomwas irritability (48%),
while the least prevalent one was euphoria (9%).




(𝑛 = 175) df 𝑝
Age (SD)a 86.5 (6.7) 84.9 (7.0) 350 0.022
Women (%)b 131 (74.0) 131 (74.9) 1 0.856
FAST (SD)c 6.0 (0.7) 6.1 (0.7) 349 0.057
MMSE (SD)c 8.4 (6.7) 7.5 (6.5) 346 0.177
Barthels ADL total score
(SD)c 8.6 (5.6) 7.9 (5.7) 339 0.216
CMAI total score (SD)c 56.2 (16.1) 56.5 (15.2) 349 0.487
MOBID-2 (SD)c 3.7 (2.5) 3.8 (2.7) 325 0.988
Medications (SD)c 3.6 (1.6) 3.4 (2.1) 318 0.146
Analgesics (%)b 122 (68.9) 117 (66.9) 1 0.404
Paracetamol (%)b 94 (53.1) 99 (56.6) 1 0.665
Opioids (%)b 51 (28.8) 43 (24.6) 1 0.292
NSAIDS (%)b 9 (5.1) 13 (7.4) 1 0.364
Psycholeptics (%)b 112 (63.3) 104 (59.4) 1 0.458
Antipsychotics (%)b 13 (7.3) 17 (9.7) 1 0.465
Anxiolytics (%)b 86 (48.6) 80 (45.7) 1 0.589
Psychosis symptoms (%)b 71 (20.2) 83 (23.6) 1 0.209
Delusion (%)b 49 (27.7) 66 (37.7) 1 0.056
Hallucination (%)b 29 (16.4) 32 (18.3) 1 0.690
Euphoria (%)b 15 (8.5) 16 (9.1) 1 0.864
Agitation symptoms (%)b 128 (36.4) 137 (38.9) 1 0.285
Agitation/aggression (%)b 74 (41.8) 85 (48.6) 1 0.253
Disinhibition (%)b 56 (31.6) 59 (33.7) 1 0.760
Irritability (%)b 84 (47.5) 85 (48.6) 1 0.956
Aberrant motor behaviour




Related to symptoms of psychosis, no associations were
found between pain and symptoms of psychosis at baseline.
During the intervention period, no reduction in the psychosis
cluster (p = 0.091, df = 1; 300), delusion (p = 0.052, df = 1; 300),
hallucination (p = 0.832, df = 1; 300), and euphoria (p = 0.507,
1; 300) was observed in response to individual pain treatment
compared to the control group from baseline and to Week 8
(Table 2, Figures 1–3). However, for people with one or more
symptoms of psychosis at baseline, a decrease was observed
in the psychosis cluster (p = 0.034, df = 1; 135) and delusion
(p = 0.031, df = 1; 135) in the intervention group compared
with the control group (Table 3, Figure 7).
At baseline, the adjusted logistic regression analysis
showed a positive association between disinhibition and level
of pain (OR: 1.18, aOR: 1.21, 95% CI: 1.10–1.34, and p < 0.001)
and between irritability and level of pain (OR: 1.11, aOR: 1.10,
95% CI: 1.01–1.21, and p = 0.032), adjusted for confounders.
During the intervention period, a decrease in the agitation
cluster (p < 0.001, df = 1; 301), agitation/aggression (p =
0.001, df = 1; 301), and aberrant motor behaviour (p = 0.017,
df = 1; 301) was found in the treatment group compared to
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Table 2: Efficacy of treating pain on psychosis and agitation.
Baseline 8 weeks
Control (n = 177) Intervention (n = 175) 𝑝a Control (n = 157) Intervention (n = 146) 𝑝a p changeb
NPI total score 31.4 (21.4) 34.8 (21.9) 0.132 26.6 (20.1) 18.9 (17.5) <0.001 <0.001
Psychosis cluster 4.8 (5.8) 6.1 (6.9) 0.087 3.7 (4.9) 3.9 (5.5) 0.682 0.091
Delusion 2.6 (3.8) 3.6 (4.3) 0.030 2.0 (3.1) 2.0 (3.2) 0.813 0.052
Hallucination 1.5 (2.9) 1.8 (3.2) 0.427 1.1 (2.3) 1.4 (2.7) 0.405 0.832
Euphoria 0.7 (2.0) 0.8 (2.2) 0.887 0.6 (1.9) 0.5 (1.8) 0.123 0.507
Agitation cluster 13.4 (10.9) 14.8 (10.9) 0.155 11.3 (10.9) 7.8 (8.3) 0.007 <0.001
Agitation/aggression 3.7 (3.9) 4.2 (4.3) 0.373 3.4 (3.8) 2.1 (3.1) 0.001 0.001
Disinhibition 3.0 (4.0) 2.9 (3.8) 0.922 2.6 (3.9) 1.7 (3.0) 0.061 0.293
Irritability 3.7 (3.7) 4.2 (4.1) 0.338 3.0 (3.4) 2.3 (3.1) 0.092 0.093
Abb. motor behaviour 3.0 (4.5) 3.5 (4.7) 0.328 2.4 (3.7) 1.7 (3.6) 0.052 0.017
aCalculated by analyzing the difference between the intervention group and control group at each measurement point using the Mann-Whitney𝑈 test.























p ≤ 0.001 p = 0.091p ≤ 0.001
Figure 1: The efficacy of treating pain on psychosis and agitation.
the control group (Table 2, Figures 1, 2, 4, 5, and 6). For
people with one or more symptoms of agitation at baseline, a
decrease during the intervention period was observed in the
agitation cluster (p < 0.001, df = 1; 228), agitation/aggression
(p = 0.004, df = 1; 228), and aberrant motor behaviour (p =
0.007, df = 1; 228) in the treatment group compared with the
control group (Table 3, Figure 8).
At baseline, the use of opioid analgesics was not associ-
ated with the prevalence of delusions (OR: 0.97, aOR: 0.96,
95% CI: 0.56–1.65, and p = 0.870) or hallucination (OR: 0.76,
aOR: 0.69, 95% CI: 0.34–1.41, and p = 0.314). Following the
intervention period at Week 8, opioids were not associated
with the prevalence of delusion (OR: 1.90, aOR: 1.89, 95% CI:
0.72–4.98, and p = 0.200) or hallucination (OR: 1.05, aOR:
1.26, 95% CI: 0.39–4.09, and p = 0.700).
5. Discussion
This study aimed to investigate the relationship between pain,











































































































Figure 2:The efficacy of pain treatment on individual neuropsychi-
atric symptoms.
psychosis and agitation, and the potential impact of opioid
analgesics on the development of hallucination and delusion
in NH patients with advanced dementia.
The study showed that treatment of pain ameliorates
the prevalence of psychosis and delusion in people with
dementia who presented at least one psychosis symptom
at baseline. It is also established that, in this study, opioid
analgesics did not increase the prevalence of hallucination
or delusion. These findings confirmed the hypothesis that
pain is a potential underlying cause for psychosis and
that proper pain management is needed in order to avoid
psychotic symptoms. This provides important information
for clinicians when pharmacological treatment options for
pain are to be evaluated. Some clinicians can be reluctant
to prescribe opioid analgesics for pain treatment of people
with dementia, oftendue to fear of anticholinergic side effects,

















































Figure 4: Development of agitation scores in clusters during
intervention and washout period.
reduced agitation, aggression, and aberrant motor behaviour.
This underlines previous findings where pain was found to
be an important underlying cause for agitation assessed with
CMAI in people with dementia. These findings highlight the
fact that proper pain assessment should be a prerequisite
when deciding treatment options for agitation in people with
dementia.
The current study was the first parallel group-controlled
trial investigating the efficacy of analgesics on psychotic
symptoms in people with advanced dementia. Although
individual pain treatment reduced psychosis in people with
psychotic symptoms, pain was, interestingly, not cross-
sectionally associated with hallucination and delusion at
baseline. Tosato et al. used data from the Minimum Data
Set (MDS) and investigated the relationship between pain
Control
Intervention





















Figure 5: Development of agitation/aggression during the interven-
tion and washout period.
Control
Intervention





















Figure 6: Development of aberrant motor behaviour during the
intervention and washout period.
Control
Intervention















Figure 7: Development of the psychosis cluster in patients with one
or more clinically significant NPS of psychosis at baseline (NPI-
NH ≥ 4).
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Table 3: Efficacy of treating pain on psychosis and agitation in patients presenting one or more clinically significant symptoms at baseline
(NPI-NH ≥ 4).
Baseline (SD) 8 weeks (SD)
Control (n = 71) Intervention (n = 83) 𝑝a Control (n = 67) Intervention (n = 70) 𝑝a 𝑝 changeb
Psychosis cluster 10.5 (4.7) 11.6 (5.9) 0.314 6.4 (5.3) 5.6 (6.1) 0.148 0.034
Delusion 5.6 (4.2) 6.9 (4.0) 0.043 3.2 (3.7) 2.9 (3.6) 0.770 0.031
Hallucination 3.2 (3.8) 3.3 (4.0) 0.813 2.1 (3.1) 2.1 (3.3) 0.987 0.925
Euphoria 1.7 (2.9) 1.4 (3.1) 0.211 1.0 (2.2) 0.5 (1.9) 0.027 0.758
Control (n = 128) Intervention (n = 137) 𝑝a Control (n = 117) Intervention (n = 113) 𝑝a p changeb
Agitation cluster 17.4 (9.7) 18.0 (9.6) 0.422 14.0 (11.0) 8.8 (8.8) <0.001 <0.001
Agitation/aggression 4.7 (4.0) 5.1 (4.2) 0.441 4.2 (4.0) 2.5 (3.3) 0.001 0.004
Disinhibition 3.9 (4.3) 3.5 (4.0) 0.618 3.3 (4.2) 1.9 (3.2) 0.008 0.211
Irritability 4.8 (3.6) 5.1 (4.1) 0.664 3.6 (3.6) 2.6 (3.2) 0.023 0.183
Abb. motor behaviour 4.0 (4.7) 4.3 (4.9) 0.639 2.9 (3.9) 1.8 (3.5) 0.008 0.007
aCalculated by analyzing the difference between the intervention group and control group at each measurement point using the Mann-Whitney𝑈 test.

















Figure 8: Development of the agitation cluster in patients with one
ormore clinically significantNPS of agitation at baseline (NPI-NH≥
4).
and psychiatric symptoms in 2822 NH residents with cog-
nitive impairment and found an association between pain
and delusion but not between pain and hallucination [19],
contrary to our results. In Tosato’s study, the interRAI MDS
2.0 instrument for long-term facilities was used to measure
psychosis and pain, while our study used the MOBID-2
Pain Scale to measure pain. Cohen-Mansfield et al. also
investigated the association between pain, delusion, and
hallucination in an adult day care population and found no
association between pain and delusion or pain and hallucina-
tion [20]. However, in contrast to our study, these people were
not residing in NHs and patients suffering from dementia
were not analyzed as a separate group. The study used the
Behavioural Pathology in Alzheimer’s disease rating scale to
measure psychosis and a questionnaire, based on the short
form of the McGill Pain Questionnaire, distributed to family
and caregivers to measure pain. Pain should be measured
by a tool thoroughly tested for psychometric properties, and
among themeasurement tools used, onlyMOBID-2 has been
tested for validity, reliability, and responsiveness [32, 33].
We used a symptom clustering largely based on a factor
analyses of the NPI-NH by Cheng et al., where the symptoms
were clustered in three main groups: agitation, mood, and
psychosis [6]. This clustering makes “clinical sense” and is in
line with other previous studies. Hollingworth et al. grouped
delusion and hallucination in a psychosis cluster, aggression
and irritability in an agitation cluster, and disinhibition,
euphoria, and aberrant motor behaviour in a behavioural
dyscontrol cluster [3]. In a four-factor solution, Selbæk and
Engedal grouped hallucination and delusion as a psychosis
cluster and aggression, irritability, disinhibition, and aberrant
motor behaviour in an agitation cluster [4]. Overall, the
clusters may be viewed as merely theoretical constructs and
changes assessed over time [4].
The reduction in psychosis was largely attributed to the
reduction of delusion, as neither hallucination nor euphoria
was reduced in response to pain treatment. This indicates
that hallucination and euphoria may not be associated
with pain. Traditionally, antipsychotics are recommended
for short-time treatment of psychosis, also in people with
dementia, despite potential harmful side effects and increased
mortality [8]. Our results suggested that hallucination and
euphoria were not associated with pain, making the use of
antipsychotics in treatment of hallucination and euphoria
more warranted than in treatment of delusion.
The use of opioid analgesics did not increase the preva-
lence of delusion or hallucination at baseline, or after the
8-week intervention. This is of key importance, because
opioid analgesics such as morphine or buprenorphine can
have multiple side effects such as confusion and delirium
caused by anticholinergic activity [24]. Notably, delirium,
psychosis, and depression have several similarities in peo-
ple with dementia, making them difficult to distinguish
and diagnose. This highlights the importance of trained
staff in order to discriminate between the more acute
state delirium and more chronic symptoms in dementia
[25].
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The reduction of agitation in response to pain treatment
was fairly expected, as previous analyses on the study pop-
ulation have shown a decrease in behavioural disturbances,
especially agitation, as measured using CMAI [9, 10]. NPI-
NH does however measure more specific symptoms in
contrast to CMAI, whichmeasures more specific behavioural
items. Therefore, the efficacy of pain treatment on the
specific symptom aberrant motor behaviour is an interesting
finding, supported by previous studies which found that
pain treatment may reduce agitation. An article by Flo et
al. reviewed studies on pain management in people with
dementia and found that pharmacological pain treatment
could reduce agitation [17]. Achterberg et al. reviewed the
efficacy of pain management in people with dementia and
found that pain can be a possible underlying cause for agi-
tation and that a thorough pain assessment and management
can ameliorate agitation [16].The present analyses also found
that there was an association between pain and disinhi-
bition and irritability at baseline. While previous studies
have found an association between pain and agitation, the
direct association between pain, disinhibition, and irritability
has not previously been described [17, 18, 35]. Our results
showed that NPS associated with pain at baseline, like
irritability and disinhibition, were not reduced in response to
pain treatment. Results also showed that NPS not associated
with pain at baseline, like agitation and delusion, were
reduced in response to pain treatment. This paradox simply
highlights the complex aetiology of NPS of agitation, and
a thorough assessment of all possible underlying causes is
important when deciding on possible treatment options for
neuropsychiatric symptoms in people with dementia. Pain
and behaviour are strongly intertwined, and the efficacy
of both behavioural interventions and pain medication can
improve both pain and behaviour [36].
Strengths and Limitations. This is the first RCT investigating
the efficacy of treating pain on psychosis. Results came from
secondary analyses from a previous study where CMAI was
the primary outcome and NPI-NH was a secondary out-
come. Inclusion criteria were therefore based on behavioural
disturbances measured using CMAI. The number of study
participants was also a limitation, as the group of patients
with psychosis at baseline were a subgroup of the original
population and a small sample. Despite this, the study is still
the largest RCT investigating the efficacy of treating pain on
psychosis and agitation.
6. Conclusion
Pain seems to be an underlying cause of psychosis and espe-
cially delusion. In addition, pain seems to be an underlying
cause of agitation, such as aberrant motor behaviour. Thus,
proper pain assessment is needed when treating these symp-
toms in people with dementia. The use of opioid analgesics
does not seem to increase the prevalence of delusion and
hallucination; therefore, the reluctance to use them may not
necessarily be to the benefit of the patient.
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